Exicure Inc is a clinical-stage biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA ... Exicure Inc is a clinical-stage biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology. 더 보기
Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to...
Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced today that it has entered into an agreement with plaintiffs to settle Colwell v. Exicure, Inc. et al., Case No. 1:21-CV-06637, a previously...
Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.02 | -0.740740740741 | 2.7 | 3.19 | 2.34 | 63227 | 2.61271798 | CS |
4 | 1.18 | 78.6666666667 | 1.5 | 6 | 1.44 | 2633813 | 2.85968349 | CS |
12 | 1.105 | 70.1587301587 | 1.575 | 6 | 1.44 | 3160558 | 2.88159497 | CS |
26 | -0.27 | -9.15254237288 | 2.95 | 6 | 1.44 | 1632796 | 2.82903775 | CS |
52 | -0.92 | -25.5555555556 | 3.6 | 6 | 1.44 | 1074387 | 2.86914689 | CS |
156 | -3.62 | -57.4603174603 | 6.3 | 16.2 | 0.423 | 2660776 | 1.37977806 | CS |
260 | -9.22 | -77.4789915966 | 11.9 | 19.2 | 0.423 | 1848747 | 2.56067968 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관